Magrolimab Falls Off The Fast Track As Gilead Reveals New Clinical Holds
Biktarvy Settlement Totals $1.25bn Up Front, 3% US Bictegravir Royalty
The company said in its fourth quarter earnings report that it would not seek accelerated approval for the drug, while it also settled an HIV drug-related intellectual property lawsuit with GSK/ViiV.
